Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)Véronique Crutel, Bruno Falissard, Cristina Albarrán Severo et al.|Journal of Autism and Developmental Disorders|2020Cited by 38